FdaApplication
NDA 218585
Identifiers
- fda_app_no: NDA218585
Properties
| Property | Value |
|---|---|
| applicant_name | LENZ THERAPEUTICS INC |
| application_type | NDA |
| approval_date | 2025-07-31 |
Revenue by product
VIZZ
| Period | Revenue |
|---|---|
| Q2 2025 | $5.0M† |
| Q2 2024 | $0.0M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VIZZ | ACECLIDINE HYDROCHLORIDE | EQ 1.44% BASE | SOLUTION/DROPS;OPHTHALMIC |
1 product